EU Launches In-depth Investigation Into Bayer-Monsanto Deal
23 August 2017 - 12:04AM
Dow Jones News
By Natalia Drozdiak
BRUSSELS-- Bayer AG and Monsanto Co. face an in-depth
investigation by the European Union into their roughly $57 billion
merger over concerns that it could lead to higher prices and fewer
options for consumers in markets including pesticides and seeds,
throwing into doubt the companies' plan to complete the tie-up by
the end of the year.
Bayer Chief Executive Werner Baumann has recently said he
expected the in-depth probe by the EU, but nonetheless counted on
completing the deal before year-end. Still an advanced
investigation by the EU is likely to complicate that timeline.
The EU on Tuesday said it was giving itself until Jan. 8, 2018
to complete the review, and regulators rarely complete their
reviews well in advance of their set deadline. That date could also
be pushed back if there are any delays or extensions to the
review.
In a statement, Bayer said it "looks forward to continuing to
work constructively with the commission with a view to obtaining
the commission's approval of the transaction by the end of this
year."
The EU on Tuesday said it was concerned the Bayer-Monsanto deal
would lead to higher prices, lower quality, less choice and less
innovation in the markets for pesticides, seeds and for plant
traits, which can be developed in laboratories and introduced in
some varieties of plants.
Bayer and Monsanto have already submitted commitments to the EU
in a bid to win approval, according to the regulator. But those
were "insufficient to clearly dismiss [the EU's] serious doubts as
to the transaction's compatibility with the EU merger
regulation."
The deal is the last in a batch of three major mergers in the
agrochemical sector that are set to reshape the industry. The EU
has already cleared Dow Chemical Co. and DuPont Co.'s deal as well
as China National Chemical Corp.'s roughly $43 billion takeover of
Swiss seed and pesticide maker Syngenta AG. In both cases the
companies had to make considerable concessions to win
clearance.
Still, that leaves Bayer-Monsanto seeking approval in an already
consolidated industry, which in turn could require Bayer and
Monsanto to offer up more extensive remedies, like selling a wider
array of assets than expected, in exchange for regulatory
approval.
Write to Natalia Drozdiak at natalia.drozdiak@wsj.com
(END) Dow Jones Newswires
August 22, 2017 09:49 ET (13:49 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.